Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 7/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6935595 | 0.93 | HTR1A (0.58) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL7613963 | 0.84 | DRD3 (0.50) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL6930794 | 0.81 | DRD2 (0.66) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL7607942 | 0.80 | HTR1A (0.58) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL7733968 | 0.80 | DRD2 (0.50) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL7733978 | 0.80 | DRD2 (0.50) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL2088381 | 0.80 | DRD2 (0.50) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL21986289 | 0.80 | DRD2 (0.54) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL2097964 | 0.80 | HTR1A (0.53) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL6934032 | 0.79 | HTR1A (0.56) | HTR1AADRA1AADRA1DADRA1BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6399614-B1 | TREATING NEUROMUSCULAR DYSFUNCTION OF LOWER URINARY TRACT VIA PERIPHERAL OR CENTRAL NERVOUS SYSTEM; SEROTONIN RECEPTOR ANTAGONIST | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-06-04 | — | — | US | claimed |
| US-20020193383-A1 | 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMOANY | 2002-12-19 | — | — | US | disclosed |
| US-6399614-B1 | TREATING NEUROMUSCULAR DYSFUNCTION OF LOWER URINARY TRACT VIA PERIPHERAL OR CENTRAL NERVOUS SYSTEM; SEROTONIN RECEPTOR ANTAGONIST | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193383-A1 | 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring | NLN, GLS, CPT1B | HTR1A 1328/4885ADRA1A 525/4885ADRA1D 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.